PCSK9与冠状动脉化之间的遗传关联是由炎症性细胞因子介导的
Weijian Wang1, Jiangping Ye2, Xinyi Hu3
1Department of Cardiology, The 904th Hospital of Joint Logistic Support Force of P.L.A., Wuxi, Jiangsu, China.
Frontiers in cardiovascular medicine
|March 4, 2026
概括
抑制PCSK9有效地通过降低脂质水平和炎症来减缓冠状动脉化 (CAC) 的进展. 纤维细胞生长因子23 (FGF23) 在这种有益的过程中起到关键的调解作用.
科学领域:
- 心血管研究研究心血管研究
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 冠状动脉化 (CAC) 与脂质代谢和炎症有关.
- 蛋白转化酶子素/素9型 (PCSK9) 抑制剂显示出血管化干预的潜力.
- 关于PCSK9抑制对血管化的影响的证据不一致.
研究的目的:
- 探索PCSK9抑制对CAC的治疗疗效.
- 调查纤维细胞生长因子23 (FGF23) 在PCSK9抑制对CAC的影响中介作用.
主要方法:
- 双样本和多变量门德尔随机化 (MR) 分析,以确定脂质资料和CAC之间的遗传联系.
- 药物点MR,局部化和中介性MR分析,以评估PCSK9作为治疗点并确定中介体.
- 在体内 (动物) 和体内 (细胞) 实验中验证PCSK9抑制对血管化的影响.
主要成果:
- 对阿波蛋白B (ApoB) 和低密度脂蛋白胆固醇 (LDL-C) 的遗传代理与CAC严重程度有积极的关联.
- PCSK9被确定为CAC的有前途的治疗标,具有共同的遗传因果关系.
- 在PCSK9-CAC轴中,FGF23充当部分调解器 (13.86%的调解率).
- 抑制PCSK9 (埃沃洛库马布) 降低了化标志物和FGF23表达体内和体外.
结论:
- 抑制PCSK9显示出减缓冠状动脉化进展的潜力.
- 纤维细胞生长因子23 (FGF23) 在PCSK9-CAC通路中扮演着炎症调解者的重要角色.
相关概念视频
01:38Inflammation
46.6K
Overview
46.6K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:25Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
973
Calcium-Scoring CT ScanA calcium-scoring CT scan, also known as coronary artery calcium (CAC) scan, detects calcium deposits in the coronary arteries. This test assesses the risk of coronary artery disease (CAD), which can lead to cardiovascular events such as angina, heart failure, and sudden cardiac arrest.A calcium-scoring CT scan is generally recommended for individuals at intermediate risk of CAD without symptoms. It includes:Men aged 40-75 and women aged 50-75: Especially those with a...
973
01:30Coronary Artery Disease I: Introduction
1.8K
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.8K
01:26Coronary Artery Disease II: Pathophysiology
1.1K
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.1K
01:30Atherosclerosis I: Introduction
2.5K
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
2.5K